Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities
Sygnature Discovery
JANUARY 17, 2023
Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications. SB is based in Glasgow and employs 55 people.
52 
Let's personalize your content